UniQure Keeps Cutting Costs With 300 More Jobs To Go

The company will cut 65% of its workforce to extend its cash runway and focus its resources on AMT-130 for Huntington's disease and three earlier-stage programs moving into Phase I/II studies.

Uniqure interior
• Source: UniQure

More from Gene Therapies

More from Advanced Therapies